Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 14;3(1):139–153. doi: 10.1002/jha2.375

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

graphic file with name JHA2-3-139-g001.jpg — Per cent change from baseline in Aiolos in CD3+ T cells (A) and CD19+ B cells (B) and in p4EBP1 (C) and pAKT (D) at 3 h post‐dose on day 1 of cycle 1 (biomarker‐evaluable population). The change in Aiolos expression in CD3+ T cells and CD19+ B cells was calculated within each avadomide‐ and CC‐223‐containing arm. *p ≤ 0.05 versus baseline; **p ≤ 0.01 versus baseline; ***p ≤ 0.001 versus baseline; DL, dose level; MEFL, molecules of equivalent fluorescence label; NS, not significant

graphic file with name JHA2-3-139-g003.jpg — Per cent change from baseline in Aiolos in CD3+ T cells (A) and CD19+ B cells (B) and in p4EBP1 (C) and pAKT (D) at 3 h post‐dose on day 1 of cycle 1 (biomarker‐evaluable population). The change in Aiolos expression in CD3+ T cells and CD19+ B cells was calculated within each avadomide‐ and CC‐223‐containing arm. *p ≤ 0.05 versus baseline; **p ≤ 0.01 versus baseline; ***p ≤ 0.001 versus baseline; DL, dose level; MEFL, molecules of equivalent fluorescence label; NS, not significant